159 related articles for article (PubMed ID: 25231751)
1. Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992-2009.
Zhang Y; Fu SS; Du XL
Med Oncol; 2014 Oct; 31(10):242. PubMed ID: 25231751
[TBL] [Abstract][Full Text] [Related]
2. Risks of Venous Thromboembolism, Stroke, Heart Disease, and Myelodysplastic Syndrome Associated With Hematopoietic Growth Factors in a Large Population-Based Cohort of Patients With Colorectal Cancer.
Du XL; Zhang Y
Clin Colorectal Cancer; 2015 Dec; 14(4):e21-31. PubMed ID: 26119923
[TBL] [Abstract][Full Text] [Related]
3. Temporal and Geographic Variations in the Receipt of Colony-Stimulating Factors and Erythropoiesis-Stimulating Agents in a Large Retrospective Cohort of Older Women With Breast Cancer From 2000 to 2009.
Du XL; Zhang Y; Hardy D
Am J Ther; 2016; 23(2):e411-21. PubMed ID: 25756469
[TBL] [Abstract][Full Text] [Related]
4. Use of Hematopoietic Growth Factors in Elderly Lung Cancer Patients Receiving Chemotherapy: A SEER-Medicare-based Study.
Rajan SS; Cai Y; Yi M; Tsai CL; Du XL
Am J Clin Oncol; 2017 Feb; 40(1):66-74. PubMed ID: 25068470
[TBL] [Abstract][Full Text] [Related]
5. Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer.
Du XL; Zhang Y; Hardy D
Cancer Causes Control; 2016 May; 27(5):695-707. PubMed ID: 27059219
[TBL] [Abstract][Full Text] [Related]
6. Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort.
Du XL; Lairson DR; Begley CE; Fang S
J Clin Oncol; 2005 Dec; 23(34):8620-8. PubMed ID: 16314624
[TBL] [Abstract][Full Text] [Related]
7. Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.
McCune JS; Sullivan SD; Blough DK; Clarke L; McDermott C; Malin J; Ramsey S
Pharmacotherapy; 2012 Jan; 32(1):7-19. PubMed ID: 22392824
[TBL] [Abstract][Full Text] [Related]
8. The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study.
Lai Y; Ye Z; Civan JM; Wang C; Cristofanilli M; Mu Z; Austin L; Palazzo JP; Myers RE; Yang H
Breast Cancer Res Treat; 2015 Sep; 153(2):407-16. PubMed ID: 26264468
[TBL] [Abstract][Full Text] [Related]
9. Racial/ethnic and gender disparities in the use of erythropoiesis-stimulating agents and blood transfusions: cancer management under Medicare's reimbursement policy.
Li M; Schulz R; Chisholm-Burns M; Wang J; Lu ZK
J Manag Care Spec Pharm; 2020 Nov; 26(11):1477-1486. PubMed ID: 33119441
[No Abstract] [Full Text] [Related]
10. Role of colony stimulating factors (CSFs) in solid tumours: results of an expert panel.
Gridelli C; Aapro MS; Barni S; Beretta GD; Colucci G; Daniele B; Del Mastro L; Di Maio M; De Petris L; Perrone F; Thatcher N; De Marinis F
Crit Rev Oncol Hematol; 2007 Jul; 63(1):53-64. PubMed ID: 17368037
[TBL] [Abstract][Full Text] [Related]
11. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
[TBL] [Abstract][Full Text] [Related]
12. Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): survey results of fifteen Paris university hospitals.
Debrix I; Madelaine I; Grenet N; Roux D; Bardin C; Le Mercier F; Fontan JE; Connor O; Pointereau A; Tilleul P
Pharm World Sci; 1999 Dec; 21(6):270-1. PubMed ID: 10658236
[TBL] [Abstract][Full Text] [Related]
13. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
Stephens JM; Bensink M; Bowers C; Hollenbeak CS
Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
[TBL] [Abstract][Full Text] [Related]
14. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
15. Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005-2017.
Schenfeld JR; Bennett CW; Li S; DeCosta LJ; Jaramillo RR; Gawade PL
J Oncol Pharm Pract; 2021 Jan; 27(1):128-142. PubMed ID: 32326872
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
J Am Geriatr Soc; 2010 Oct; 58(10):1885-95. PubMed ID: 20840455
[TBL] [Abstract][Full Text] [Related]
17. Travel burden associated with granulocyte colony-stimulating factor administration in a Medicare aged population: a geospatial analysis.
Stephens JM; Bensink M; Bowers C; Hollenbeak CS
Curr Med Res Opin; 2018 Aug; 34(8):1351-1360. PubMed ID: 28722536
[TBL] [Abstract][Full Text] [Related]
18. Impact of cancer supportive care pathways compliance on emergency department visits and hospitalizations.
Kreys ED; Kim TY; Delgado A; Koeller JM
J Oncol Pract; 2014 May; 10(3):168-73. PubMed ID: 24839275
[TBL] [Abstract][Full Text] [Related]
19. Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.
Wright JD; Neugut AI; Wilde ET; Buono DL; Malin J; Tsai WY; Hershman DL
J Clin Oncol; 2011 Sep; 29(25):3408-18. PubMed ID: 21810679
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
